Open an account

Synvista Therapeutics

SYNI · OTC

$0.00+$0.00 (+0.00%)TodayMarket open · · Delayed 15 min
No price history for this range.

About SYNI

Synvista Therapeutics, Inc. is a biotechnology company, which engages in the development of diagnostic tests and pharmaceutical drugs for the treatment of diabetes. The company is headquartered in Montvale, New Jersey and currently employs 9 full-time employees. The firm's lead drug candidate, alagebrium chloride or alagebrium, is an advanced glycation end-product crosslink breaker being developed for diastolic heart failure (DHF). Synvista is also managing a discovery and development program to produce small molecule drugs that mimic the enzyme glutathione peroxidase (GPx). One of the Company’s GPx mimetics, ALT-2074, is in Phase II clinical trials.

Employees
9
Headquarters
Montvale, New Jersey
Listed
Nov 1, 1991
Sector
Health Care
Industry
Pharmaceuticals

SYNI key statistics

Market cap
3
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
260
Volume
20
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.00
52 Week low
$0.00

Synvista Therapeutics (SYNI) at a glance

Synvista Therapeutics (SYNI) last traded at $0.00, with a market cap of 3 and a price-to-earnings ratio of 0.00.

Volume so far is 20 shares, below the average of 260 shares a day.

Synvista Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY08 it reported -$2.03 per share against an estimate of -$1.03.

SYNI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 22.3% on average.

  1. Q3 FY02: reported -$9.50 per share against an estimate of -$10.20
  2. Q4 FY02: reported -$6.00 per share against an estimate of -$10.20
  3. Q1 FY03: reported -$9.00 per share against an estimate of -$10.97
  4. Q2 FY03: reported -$8.50 per share against an estimate of -$9.18
  5. Q3 FY03: reported -$3.50 per share against an estimate of -$7.39
  6. Q4 FY03: reported -$4.50 per share against an estimate of -$5.61
  7. Q2 FY04: reported -$5.50 per share against an estimate of -$6.12
  8. Q2 FY08: reported -$2.03 per share against an estimate of -$1.03

Similar companies

Companies in the same industry as Synvista Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.